Watch the Video Now...
Sarcomatrix Therapeutics is a pre-clinical biotechnology company dedicated to developing innovative treatments for muscle-wasting diseases, with an initial focus on muscular dystrophy. Our primary goal is to create oral drugs that help maintain and regenerate muscle, potentially transforming the treatment landscape for these debilitating conditions.
Investment Opportunity
Now is your chance to invest in the pre-revenue and pre-commercialization stages of development.
Watch the Video Now...
Sarcomatrix Therapeutics is a pre-clinical biotechnology company dedicated to developing innovative treatments for muscle-wasting diseases, with an initial focus on muscular dystrophy. Our primary goal is to create oral drugs that help maintain and regenerate muscle, potentially transforming the treatment landscape for these debilitating conditions.
Investment Opportunity
Now is your chance to invest in the pre-revenue and pre-commercialization stages of development.
Why Invest in Sarcomatrix?
Sarcomatrix is working to unveil novel therapeutics that will disrupt the $2B Duchenne Muscular Dystrophy market, where current treatments merely delay progression.
With a projected $18B global market by 2030 and Duchenne Muscular Dystrophy representing a quarter of it, we believe our approach holds disruptive medical potential.
We've secured $8M in NIH grants in combination with our research partner, Strykagen. Your investment helps our mission-driven approach to reshape treatment paradigms.
Join us in transforming treatment possibilities and shaping a healthier future...
Why Invest in Sarcomatrix?
Sarcomatrix is working to unveil novel therapeutics that will disrupt the $2B Duchenne Muscular Dystrophy market, where current treatments merely delay progression.
With a projected $18B global market by 2030 and Duchenne Muscular Dystrophy representing a quarter of it, we believe our approach holds disruptive medical potential.
We've secured $8M in NIH grants in combination with our research partner, Strykagen. Your investment helps our mission-driven approach to reshape treatment paradigms.
Join us in transforming treatment possibilities and shaping a healthier future...
WANT IN? SUBSCRIBE BELOW FOR MORE INFORMATION.
I Consent to Receive SMS Notifications, Alerts & Occasional Marketing Communication from company. Message frequency varies. Message & data rates may apply. You can reply STOP to unsubscribe at any time.
Sarcomatrix Therapeutics is well-positioned to make significant advancements in the treatment of muscle-wasting diseases. With a robust management team, innovative approach, and strong market potential, we present a promising investment opportunity for those looking to support groundbreaking medical research and development.
Sarcomatrix Therapeutics is well-positioned to make significant advancements in the treatment of muscle-wasting diseases. With a robust management team, innovative approach, and strong market potential, we present a promising investment opportunity for those looking to support groundbreaking medical research and development.
Our Team
David Craig
President, CEO and Chairman of the Board
With over 30 years experience developing products in the life sciences industry, David has worked in building biotechnology companies and supporting their initial fundraising efforts, growth and commercialization. He has previously held senior positions at Amgen, AstraZeneca, Gilead and Alexion. He will be providing Form C sign-off as the Company's Principal Accounting Officer.
David Alan Maine
Chief of Staff
I'm an economist who is valued as a decision-support partner with company founders, co-founders, and academic professors. By providing distinct analysis, data sourcing, market research, financial modeling, business acumen and critical decision-making, I am able to refine business models and value propositions into efficient operational practices to accelerate commercialization. Driven by opportunity to improve global health, I have partnered with several firms to bridge early stage development processes into real world applications.
Ryan David Wuebbles
Chief Scientific Officer
Dr. Ryan Wuebbles received his PhD in 2009 from the University of Illinois. He been involved in researching muscular dystrophy causes and therapeutics for over 20 years, including 15 years working with Dr. Burkin developing the Laminin and small molecule programs.
Follow Us On Social Media
Follow Us On Social Media